Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal

Size: px
Start display at page:

Download "Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal"

Transcription

1 Evolution of XDR-TB in KwaZulu-Natal A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal

2 Drug resistance among culture positive TB cases by South African Province ( ) Any Drug Resistance (%) MDR (%) Province No History of Prior History of Prior TB No History of Prior History of Prior TB TB Treatment** Treatment** TB Treatment** Treatment** Eastern Cape Free State*** Gauteng KwaZulu-Natal Limpopo Mpumalanga North West Western Cape South Africa (Weyer et al, 2004)

3 53 cases of XDR-TB diagnosed in CoSH in Tugela Ferry (early 2005) Proportion Surviving Days since Sputum Collected (Gandhi et al, 2006)

4 Questions What happened between 2002 and 2005? Where did these 53 XDR cases come from? Was (is) this a hospital outbreak at CoSH or a more wide spread problem? Are the data an underrepresenting the MDR situation?

5 1396 cases suspected of PTB attending CoSH out-patient department 475 culture positive (2005)? infected in hospital 185 MDR 30 XDR 14 history of prior hospitalisation? infected in community 16 never hospitalised community transmission (Gandhi et al, 2006)

6 Questions What happened between 2002 and 2005? Where did these 53 XDR cases come from? Was (is) this a hospital outbreak at CoSH or a more wide spread problem? Are the data an underrepresenting the MDR situation?

7 Proportion of F15/LAM4/KZN strains amongst genotyped isolates Year Total no. genotyped No. (%) KZN strains Total no. (%) MDR No. (%) MDR KZN strains (2) 9 (3) 4 (44) (19) 27 (26) 12 (44) (15) 56 (40) 15 (27) (31) 24 (75) 8 (33) (9) 8 (35) 1 (13) (17) 15 (32) 4 (27) (31) 28 (62) 8 (29) (17) 64 (73) 13 (20) (8) 38 (23) 10 (26) Total (11) 269 (31) 75 (28) p < (Pillay and Sturm, 2007)

8 Fig 1. Resistance development in the KZN family of strains of Mycobacterium tuberculosis from 1994 till 2006 Resistance found for the first time in: Resistance to: none IE IS ISE IR IRE IRET IREEtT IRS IRSE IRSEEtT IRSETCa IRSEEtTK IRSEEtFq IRSEEtKFq IRSEKFq I isoniazid; S streptomycin; E ethambutol; Et ethionamide; R rifampicin; T thiacetazone Ca capreomycin; K kanamycin/amikacin; Fq fluoroquinolones (Pillay and Sturm, CID, Dec. 2007)

9 Situation in KZN in 2006/07 Culture and DST results of all patients in KZN on sputum specimens received between 1 Jan and 30 June 2007 Susceptibility testing done routinely for: isoniazide rifampicine ethambutol streptomycin kanamycine ofloxacin

10 KwaZulu-Natal Province Population size: 9,616, health districts divided in subdistricts

11 Differences in number of TB cases in districts of KZN District Population New TB cases MDR Cases XDR Cases Amajuba 477, ethekwini 3,152, ilembe 571, Sisonke 304, Ugu 718, Umgungundlovu 946, Umkhanyakude 584, Umzinyathi 465, Uthukela 670, Uthungulu 903, Zululand 820, Total 9,616,

12 Differences in incidence of TB cases in districts of KZN Incidence of new TB Incidence of MDR Incidence of XDR District (per /yr) (per /yr) (per /yr) Amajuba ethekwini ilembe Sisonke Ugu Umgungundlovu Umkhanyakude Umzinyathi Uthukela Uthungulu Zululand Total

13 Association between no. of new cases of TB diagnosed by culture and percentage MDR

14 Differences in rates of MDR and XDR cases in districts of KZN No. of MDR per No. of XDR per District 100 new TB cases 100 new TB cases Amajuba ethekwini ilembe Sisonke Ugu Umgungundlovu Umkhanyakude Umzinyathi Uthukela Uthungulu Zululand Total

15 From 2005, CoSH is the only health care facility with culture diagnostics performed on all possible TB cases Includes Msinga (CoSH)

16 How resistant is our XDR TB?

17 Fig 1. Resistance development in the KZN family of strains of Mycobacterium tuberculosis from 1994 till 2006 Resistance found for the first time in: Resistance to: none IE IS ISE IR IRE IRET IREEtT IRS IRSE IRSEEtT IRSETCa IRSEEtTK IRSEEtFq IRSEEtKFq IRSEKFq I isoniazid; S streptomycin; E ethambutol; Et ethionamide; R rifampicin; T thiacetazone Ca capreomycin; K kanamycin/amikacin; Fq fluoroquinolones (Pillay and Sturm, CID, Dec. 2007)

18 Genotypic resistance in F15/LAM4/KZN XDR isolates (n=52) Mutations in rss gene: 100 % resistance to streptomycin, kanamycine, amikacin and capreomycin Mutations in pcn A gene: 69 % resistance to pyrazinamide

19 MICs of M. tuberculosis isolates Table 2b: MICs of 11 M. tuberculosis isolates in Middlebrook 7H9 broth Median (range) MIC (mg/l) Susc. MDR XDR PAS ( ) Capreomycin (4-16) Linezolid 2 (0.5-2) 0.5 ( ) 1 (0.5-4) Merepenem (8-32) Meropenem-clavulanic acid 1 1 (1-2) 1 (0.5-4)

20 How resistant is XDR M.tuberculosis in KZN? Most isolates are resistant to: 1. isoniazid 2. rifampicin 3. ethambutol 4. pyrazinamide 5. streptomycin 6. kanamycin 7. amikacin 8. capreomycin 9. ofloxacin 10.ethionamide

21 Tuberculosis in the Msinga sub-district compared with other parts of KwaZulu- Natal no. (%*) no. of MDR per no. of XDR per population new TB cases 100 new TB cases 100 new TB cases Msinga sub-district 160, (0.68) Umzinyathi without Msinga 305, (0.12) districts with academic centre** (n=3) 4,683, (0.32) 11 1 other districts ** (n=9) 4,466, (0.09) 28 2 * percentage of the population ** MDR and XDR: average of the districts How does Msinga (CoSH) differ from the rest of the province?

22 Differences between Msinga subdistrict and the rest of the province Msinga sub-district Culture and DST on all on first contact No delay in DST results Rest of province Culture and DST on indication Delay in DST results No delay in appropriate treatment Delay in appropriate treatment

23 53 cases of XDR-TB diagnosed in CoSH in Tugela Ferry Proportion Surviving Days since Sputum Collected (Gandhi et al, 2006)

24 Referral for treatment of MDR/XDR cases Total number of MDR/XDR diagnosed between 1 Jan 2006 and 30 June Total number referred for treatment to MDR/XDR referral hospital 1439 (40%) Waiting list for admission

25 Is Msinga (CoSH) different from the rest of the province? May be not! Many patients in the rest of the province die: before a specimen is taken or before the DST results become available

26 Clonal spread? If so, did it start in Msinga /Tugela Ferry/CoSH?

27 Whole genome sequencing F15/LAM4/KZN XDR isolates 8 sequences completed all same mutations in resistance genes

28 Geographical distribution of sequenced XDR isolates 8 isolates 7 locations 4 districts Tugela Ferry

29 Whole genome sequencing F15/LAM4/KZN XDR isolates 8 sequences completed All same mutations in resistance genes Isolates from 7 different geographical locations 4 districts Suggests clonal spread number needs to be extended

30 Clonal spread? If so, did it start in Msinga /Tugela Ferry/CoSH?

31 Tuberculosis in the Msinga sub-district compared with other parts of KwaZulu- Natal no. (%*) no. of MDR per no. of XDR per population new TB cases 100 new TB cases 100 new TB cases Msinga sub-district 160, (0.68) Umzinyathi without Msinga 305, (0.12) districts with academic centre** (n=3) 4,683, (0.32) 11 1 other districts ** (n=9) 4,466, (0.09) 28 2 * percentage of the population ** MDR and XDR: average of the districts

32 Origin of XDR isolates in 1 st half of 2005 (laboratory database) Tugela Ferry Other locations January - March 15 6 April - June Did it start in Tugela Ferry? We will never know!

33 Conclusions KwaZulu-Natal has an enormous TB burden MDR and XDR strains are present throughout the province F15/LAM4/KZN isolates from 2005 were already TDR Sequence data suggest clonal spread of the XDR phenotype of F15/LAM4/KZN Prevalence data and time-of-first appearance data suggest that it may have started in Msinga district/tugela Ferry/CoSH

34 The team Durban Prashini Moodley Manormoney Pillay Staff and students of the TB research laboratory in at NRMSM Tugela Ferry Tony Moll Staff at Church of Scotland Hospital Albert Einstein/Yale Sarita Shah Neel Gandhi Gerald Friedland Bill Jacobs and his team

The emerging threat of multidrug resistant TB: Global and local challenges and solutions

The emerging threat of multidrug resistant TB: Global and local challenges and solutions Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR

More information

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948

More information

Transmission of XDR TB

Transmission of XDR TB Transmission of XDR TB Neel Gandhi, MD Tugela Ferry Care & Research Collaboration (TF CARES) Albert Einstein College of Medicine November 5, 2008 TF CARES Tugela Ferry Care and Research Collaboration Background

More information

HIV and Drug-Resistant TB Reflections from rural Tugela Ferry

HIV and Drug-Resistant TB Reflections from rural Tugela Ferry HIV and Drug-Resistant TB Reflections from rural Tugela Ferry Neel R. Gandhi, MD Tugela Ferry Care & Research Collaboration (TF CARES) Albert Einstein College of Medicine 3 March 2010 HIV & Drug-Resistant

More information

Diagnosis of drug resistant TB

Diagnosis of drug resistant TB Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million

More information

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe

More information

Treatment of Extensively Drug Resistant Tuberculosis Among Patients with HIV Infection in South Africa

Treatment of Extensively Drug Resistant Tuberculosis Among Patients with HIV Infection in South Africa Treatment of Extensively Drug Resistant Tuberculosis Among Patients with HIV Infection in South Africa Max O Donnell, Nesri Padayatchi, Iqubal Master, Garth Osburn, Robert Horsburgh Outline 1. XDR-TB in

More information

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin

More information

9 Tuberculosis. Introduction. Lieve Vanleeuw and Marian Loveday

9 Tuberculosis. Introduction. Lieve Vanleeuw and Marian Loveday 9 Tuberculosis Lieve Vanleeuw and Marian Loveday Introduction Tuberculosis (TB) remains a major health problem in South Africa. Although TB incidence has been declining in South Africa since 2009 and deaths

More information

Management of Drug-resistant Tuberculosis (DR-TB)

Management of Drug-resistant Tuberculosis (DR-TB) Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical

More information

Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is

Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is Yale AIDS Program Section of Infectious Diseases Yale University School of Medicine Sheela Shenoi MD MPH September 20, 2012

More information

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa Neel R Gandhi, Anthony Moll, A Willem Sturm, Robert Pawinski,

More information

KWAZULU-NATAL. connecting. collecting. collaborating A SUPPORT SERVICES DIRECTORY SERIES

KWAZULU-NATAL. connecting. collecting. collaborating A SUPPORT SERVICES DIRECTORY SERIES KWAZULU-NATAL A SUPPORT SERVICES DIRECTORY SERIES 6 2013 collecting connecting collaborating Introducing a new identity for HIVAN The Centre for HIV/AIDS Networking (HIVAN) has a long history of working

More information

Progress Report March 2016

Progress Report March 2016 Progress Report March 2016 Table of Contents Background to project 3 Assays performed to date 3 Correctional Services 5 Peri-Mining 6 Rif Concordance 7 Training: Laboratory and Clinical 7 Challenges identified

More information

SA: Percentage [Source: DHIS]

SA: Percentage [Source: DHIS] 10 Tuberculosis Lieve Vanleeuw, Yoliswa Mzobe and Marian Loveday Introduction The End TB Strategy adopted by the World Health Assembly in 2014 aims to end the global TB epidemic with targets to reduce

More information

5 PMTCT Indicators Linda Mureithi

5 PMTCT Indicators Linda Mureithi 5 PMTCT Indicators Linda Mureithi The success in scale-up of South Africa s prevention of mother-to-child transmission (PMTCT) programme has been widely documented. a,b This has been achieved through progressive

More information

2014/15 % 2013/14 % 2012/13 %

2014/15 % 2013/14 % 2012/13 % 5 PMTCT Mathilda Ntloana, Ahmad Haeri Mazanderani and Gayle Sherman This chapter presents three core national indicators used to assess the progress and performance of key services in the prevention of

More information

9 Reproductive health

9 Reproductive health 9 Reproductive health Manala Makua The reproductive health chapter covers two indicators, namely cervical cancer screening rate and couple year protection rate (CYPR). 9.1 Couple year protection rate Couple

More information

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention

More information

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever

More information

Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR)

Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Tuberculosis (TB). AH Diacon*, A Pym**, MP Grobusch, G. Churchyard, T De

More information

Expanded Programme on Immunisation South Africa Revised immunisation schedule from December 2015

Expanded Programme on Immunisation South Africa Revised immunisation schedule from December 2015 8 Immunisation Yin Yin Aung and Nonhlanhla Rosemary Dlamini Immunisation of children is a successful public health measure to reduce infant morbidity and mortality from vaccinepreventable diseases. a In

More information

Progress towards Malaria Elimination in South Africa. Durban, South Africa 10 September 2011

Progress towards Malaria Elimination in South Africa. Durban, South Africa 10 September 2011 Progress towards Malaria Elimination in South Africa Durban, South Africa 10 September 2011 Outline 1. Malaria Elimination Strategy 2. Systematic Approach to Elimination in South Africa 3. Malaria Situation

More information

10 HIV Thesandree Padayachee

10 HIV Thesandree Padayachee 10 HIV Thesandree Padayachee South Africa remains at the centre of the global HIV and AIDS epidemic, with an estimated 6.8 million people affected by the disease at the end of 2014. a While the country

More information

Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa

Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa Tropical Medicine and International Health doi:10.1111/j.1365-3156.2010.02590.x volume 15 no 10 pp 1179 1184 october 2010 Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South

More information

9 Tuberculosis Marian Loveday and Lieve Vanleeuw

9 Tuberculosis Marian Loveday and Lieve Vanleeuw 9 Tuberculosis Marian Loveday and Lieve Vanleeuw Introduction Tuberculosis (TB) remains a major health problem in South Africa, with the BRICS countries (Brazil, the Russian Federation, India, China and

More information

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa 2005 2010 BK Moore 1, E Anyalechi 1, M van der Walt 2, S Smith 1, L Erasmus 3, J Lancaster 2, S Morris 1, N Ndjeka

More information

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University Transmission of MDR/XDR Tuberculosis in Shanghai Qian Gao Shanghai Medical College Fudan University Drug Resistant TB in China The Highest DR-TB Burden Country New TB cases/year Cases with any DR MDR XDR

More information

Kristina Wallengren, PhD MPH

Kristina Wallengren, PhD MPH Kristina Wallengren, PhD MPH Head of Clinical Research K-RITH South Africa K-RITH S AIM: TO CONDUCT EXCELLENT BASIC SCIENCE IN TB AND HIV XDR TB outbreak in Tugela Ferry, KwaZulu-Natal, 2005 XDR TB PREVALENCE

More information

The National Strategic Plan for HIV, TB and STIs: April 2017-March 2022

The National Strategic Plan for HIV, TB and STIs: April 2017-March 2022 The National Strategic Plan for HIV, TB and STIs: April 2017-March 2022 Presentation to NSP Satellite 8 th SA AIDS Conference 13 June 2017 Key challenges -HIV,TB,STIs 7 million people living with HIV 270

More information

Update on Management of

Update on Management of Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

Online Annexes (5-8)

Online Annexes (5-8) 2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings

More information

11 HIV and AIDS Male condom distribution coverage. Tshepo Molapo, Lebogang Schultz, Refilwe Sello and Lesego Mawela

11 HIV and AIDS Male condom distribution coverage. Tshepo Molapo, Lebogang Schultz, Refilwe Sello and Lesego Mawela 11 HIV and AIDS Tshepo Molapo, Lebogang Schultz, Refilwe Sello and Lesego Mawela This chapter covers three indicators, namely: (i) male condom distribution coverage (ii) HIV testing coverage and (iii)

More information

Online Annexes (5-8)

Online Annexes (5-8) Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO

More information

RESEARCH. 507 June 2017, Vol. 107, No. 6. These open-access articles are distributed under Creative Commons licence CC-BY-NC 4.0.

RESEARCH. 507 June 2017, Vol. 107, No. 6. These open-access articles are distributed under Creative Commons licence CC-BY-NC 4.0. These open-access articles are distributed under Creative Commons licence CC-BY-NC 4.0. RESEARCH Analysis of HIV disease burden by calculating the percentages of patients with CD4 counts

More information

National Xpert MTB/RIF Programme

National Xpert MTB/RIF Programme National Xpert MTB/RIF Programme 1. Background to Project This project was initiated at the request of the Honorable Minister of Health, Dr Aaron Motsoaledi, in early 2011, following the World Health Organization

More information

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana

More information

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)

More information

Assessing the programmatic management of drug-resistant TB

Assessing the programmatic management of drug-resistant TB Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many

More information

Ken Jost, BA, has the following disclosures to make:

Ken Jost, BA, has the following disclosures to make: Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict

More information

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH. The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,

More information

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Human Journals Review Article August 2016 Vol.:1, Issue:3 All rights are reserved by Mr. Suraj Narayan Mali et al. Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Keywords: Totally Drug-resistant

More information

Multi Drug Resistant tuberculosis (MDR-TB)

Multi Drug Resistant tuberculosis (MDR-TB) Multi Drug Resistant tuberculosis (MDR-TB) Vincent Jarlier Pitié-Salpêtrière hospital Paris, France March 24th 1882 : announcement of Discovery of TB bacillus National reference center for mycobacteria

More information

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory

More information

7 Immunisation. 7.1 Immunisation coverage under 1 year. Trisha Ramraj and Witness Chirinda

7 Immunisation. 7.1 Immunisation coverage under 1 year. Trisha Ramraj and Witness Chirinda 7 Immunisation Trisha Ramraj and Witness Chirinda 7.1 Immunisation coverage under 1 year Immunisation coverage under 1 year measures the percentage of children under 1 year of age who have received all

More information

Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa

Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa Helen S. Cox 1,2,3 *, Cheryl McDermid 2, Virginia Azevedo 4, Odelia Muller

More information

Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China

Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Multi-Ethnic Region, Xinjiang Uygur Autonomous Region, China Ying-Cheng Qi 1., Mai-Juan Ma 2., Dong-Jun Li 3, Mei-Juan Chen 1, Qing-Bin

More information

Name change of the invasive fruit fly and update on its pest status in South Africa

Name change of the invasive fruit fly and update on its pest status in South Africa Name change of the invasive fruit fly and update on its pest status in South Africa Fruit flies are the bane of many fruit growers existence, but in this case it s better the devil you know, than the one

More information

Annual surveillance report 2016

Annual surveillance report 2016 Annual surveillance report 216 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,

More information

Drug-resistant tuberculosis (DR-TB) is a significant threat to efforts to end TB in

Drug-resistant tuberculosis (DR-TB) is a significant threat to efforts to end TB in Drug-resistant tuberculosis in South Africa: history, progress and opportunities for achieving universal access to diagnosis and effective treatment 15 Authors: Helen Cox i Lindy Dickson-Hall ii Waasila

More information

SOUTH AFRICA S TB BURDEN - OVERVIEW

SOUTH AFRICA S TB BURDEN - OVERVIEW SOUTH AFRICA S TB BURDEN - OVERVIEW Dr Aaron Motsoaledi, MP: Chairperson of the Board, Stop TB Partnership Minister of Health, South Africa 31 January 2014, Cape Town South Africa s TB Burden Global TB

More information

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words

More information

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first

More information

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries

More information

The Emerging Threat of Multidrug-Resistant Tuberculosis: Global and Local Challenges and Solutions

The Emerging Threat of Multidrug-Resistant Tuberculosis: Global and Local Challenges and Solutions The Emerging Threat of Multidrug-Resistant Tuberculosis: March 3-4, 2010 Roode Vallei Country Lodge With the development of antibiotics in the twentieth century, tuberculosis gradually lost its central

More information

Downloaded from:

Downloaded from: Heller, T; Lessells, RJ; Wallrauch, CG; Barnighausen, T; Cooke, GS; Mhlongo, L; Master, I; Newell, ML (2010) Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South

More information

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa The new england journal of medicine Original Article Transmission of Extensively Drug-Resistant Tuberculosis in South Africa N. Sarita Shah, M.D., M.P.H., Sara C. Auld, M.D., James C.M. Brust, M.D., Barun

More information

Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa

Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa SUPPLEMENT ARTICLE CSE Global Theme Issue on Poverty and Human Development Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy

More information

FIND and NDWG symposium Panel Discussion. Martina Casenghi, NDWG Core Group

FIND and NDWG symposium Panel Discussion. Martina Casenghi, NDWG Core Group FIND and NDWG symposium Panel Discussion Martina Casenghi, NDWG Core Group 48 Union World Conference, Guadalajara October 11th 2017 Molecular tests for diagnosis of TB and drug resistance 2008 Dec 2010

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment

More information

Programmatically Selected Multidrug-Resistant Strains Drive the Emergence of Extensively Drug-Resistant Tuberculosis in South Africa

Programmatically Selected Multidrug-Resistant Strains Drive the Emergence of Extensively Drug-Resistant Tuberculosis in South Africa Programmatically Selected Multidrug-Resistant Strains Drive the Emergence of Extensively Drug-Resistant Tuberculosis in South Africa Borna Müller 1,2,3., Violet N. Chihota 1,4., Manormoney Pillay 5, Marisa

More information

HA Convention 2016 : Special Topic Session 3 May 2016

HA Convention 2016 : Special Topic Session 3 May 2016 HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis

More information

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility

More information

Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011

Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011 Tropical Medicine and International Health doi:10.1111/tmi.12183 volume 00 no 00 Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011 Nathan Kapata 1,2,3,5, Pascalina Chanda-Kapata

More information

Responding to a TB Event Bismarck, North Dakota June 24-25, 2008

Responding to a TB Event Bismarck, North Dakota June 24-25, 2008 Responding to a TB Event Bismarck, North Dakota June 24-25, 2008 TB Epidemiology: Global and State Lynelle Phillips, RN, MPH June 24, 2008 TB Epidemiology Global and State Lynelle Phillips RN MPH Nurse

More information

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa

Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa Charlotte L. Kvasnovsky, J. Peter Cegielski, Martie L. van der Walt

More information

Annual surveillance report 2015

Annual surveillance report 2015 Annual surveillance report 215 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,

More information

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case

More information

M ultidrug resistant (MDR) tuberculosis (TB) has

M ultidrug resistant (MDR) tuberculosis (TB) has 1106 ORIGINAL ARTICLE Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome H S Schaaf, K Shean, P R Donald... See end of article for authors affiliations...

More information

Low treatment initiation among multi-drug resistant tuberculosis patients in Gauteng, South Africa, 2011

Low treatment initiation among multi-drug resistant tuberculosis patients in Gauteng, South Africa, 2011 Low treatment initiation among multi-drug resistant tuberculosis patients in Gauteng, South Africa, 2011 J.I. Ebonwu, 1, 2 K.S. Tint, 1, 2 C. Ihekweazu 3, 4 1 South African Field Epidemiology and Laboratory

More information

Health FITNESS & NUTRITION HEALTH CARE POLICY MENTAL HEALTH & BEHAVIOR. Mike Hutchings/Reuters ED PRINT REPRINTS SAVE SHARE

Health FITNESS & NUTRITION HEALTH CARE POLICY MENTAL HEALTH & BEHAVIOR. Mike Hutchings/Reuters  ED PRINT REPRINTS SAVE SHARE Page 1 of 5 HOME PAGE MY TIMES TODAY'S PAPER VIDEO MOST POPULAR TIMES TOPICS Free 14-Day Trial Welcome, susannadodgson Member Center Log Out Health Health All NYT WORLD U.S. N.Y. / REGION BUSINESS TECHNOLOGY

More information

Background and Rationale for TB Infection Control

Background and Rationale for TB Infection Control Background and Rationale for TB Infection Control Henry M. Blumberg, M.D. Professor of Medicine and Epidemiology Program Director, Div. of Infectious Diseases Emory University School of Medicine and Hospital

More information

TB Program and Epidemic aka B2B

TB Program and Epidemic aka B2B TB Program and Epidemic aka B2B Nulda Beyers On behalf of DTTC BOD Workshop 30 September2013 Trend in tuberculosis incidence, selected countries in Africa 1400 1200 Rate per 100,000 1000 800 600 400 200

More information

Index. Research Objective. Health Issues in SA Non-communicable diseases Diabetes Cancer Hypertension. Communicable Diseases HIV AIDS TB

Index. Research Objective. Health Issues in SA Non-communicable diseases Diabetes Cancer Hypertension. Communicable Diseases HIV AIDS TB Index Research Objective Health Issues in SA Non-communicable diseases Diabetes Cancer Hypertension Communicable Diseases HIV AIDS TB Obesity & Weight Loss Customer Segmentation Competitive Environment

More information

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing 1. Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices 1.1 Overview: Mycobacterial Culture, Identification,

More information

Genotyping of Multidrug-Resistant Strains of Mycobacterium tuberculosis in the Limpopo Province. Kgasha Matete Olga

Genotyping of Multidrug-Resistant Strains of Mycobacterium tuberculosis in the Limpopo Province. Kgasha Matete Olga Genotyping of Multidrug-Resistant Strains of Mycobacterium tuberculosis in the Limpopo Province by Kgasha Matete Olga DISSERTATION Submitted in fulfillment of the requirements for the degree of MASTER

More information

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012 TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant

More information

Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending

Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending EDITORIAL TUBERCULOSIS Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending Max Salfinger 1 and Giovanni Battista Migliori 2 Affiliations: 1 Dept of Medicine, National

More information

Public Disclosure Authorized. Public Disclosure Authorized. Public Disclosure Authorized. Public Disclosure Authorized

Public Disclosure Authorized. Public Disclosure Authorized. Public Disclosure Authorized. Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Determinants of CD4 immune recovery among individuals on antiretroviral therapy in South

More information

March 24, 2007 will mark the 125th anniversary of Robert

March 24, 2007 will mark the 125th anniversary of Robert Eur Respir J 2007; 29: 423 427 DOI: 10.1183/09031936.00001307 CopyrightßERS Journals Ltd 2007 EDITORIAL 125 years after Robert Koch s discovery of the tubercle bacillus: the new XDR-TB threat. Is science

More information

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza

More information

11 Non-communicable diseases

11 Non-communicable diseases 11 Non-communicable diseases Annibale Cois Undoubtedly, non-communicable diseases (Ds) are playing an increasingly important role in defining South Africa s health profile, and they are an essential element

More information

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014 TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Tuberculosis: The Big Picture And Challenge of Drug-resistance

Tuberculosis: The Big Picture And Challenge of Drug-resistance 5 th APHL National Conference on Laboratory Aspects of Tuberculosis August 11-13, 2008 San Diego, California Tuberculosis: The Big Picture And Challenge of Drug-resistance RADM Kenneth G. Castro, M.D.

More information

CLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL

CLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL CLINICAL EXPERIENCE OF TREATING XDR- TB AT JOSE PEARSON TB HOSPITAL BY DR LIMPHO RAMANGOAELA B.Sc.Ed(NUL),MBCHB(UKZN) 20 TH OCTOBER 2017 Livingstone Resource Centre. JOSE PEARSON TB HOSPITAL Out Line Overview

More information

Laboratory Diagnosis for MDR TB

Laboratory Diagnosis for MDR TB Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe

More information

TOG The Way Forward

TOG The Way Forward TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till

More information

Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic

Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic A. Kadyrov, PhD in Medicine Director

More information

14 Burden of disease. Methodology. Pam Groenewald, Debbie Bradshaw, Candy Day and Ria Laubscher. Data source

14 Burden of disease. Methodology. Pam Groenewald, Debbie Bradshaw, Candy Day and Ria Laubscher. Data source Burden of disease Pam Groenewald, Debbie Bradshaw, Candy Day and Ria Laubscher This is the sixth attempt to assess and compare the cause of death profiles for each of the health districts in South Africa.

More information

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions

More information

TB 101 Disease, Clinical Assessment and Lab Testing

TB 101 Disease, Clinical Assessment and Lab Testing TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain

More information

Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011

Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Original Research Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Hoa Binh Nguyen, ab Nhung Viet Nguyen, ac Huong Thi Giang Tran,

More information

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries Optimising patient care in MDR TB with existing molecular screening tests in high burden countries Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,India Outline What is the best empiric

More information

A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB.

A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB. ERJ Express. Published on September 13, 2013 as doi: 10.1183/09031936.00140513 A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB. Helen R. Stagg a,b,c, *, Ted Cohen

More information

Building a South African Exchange Program: Update and Future Goals

Building a South African Exchange Program: Update and Future Goals Building a South African Exchange Program: Update and Future Goals Highlights from the November 2015 Trip Set up ENT clinic at the Church of Scotland Hospital in rural Tugela Ferry, South Africa Saw ~400

More information

TB in the Southern African mining sector and across the sub-region STOP TB Partnership Board Meeting By Dr Aaron Motsoaledi Minister of Health South

TB in the Southern African mining sector and across the sub-region STOP TB Partnership Board Meeting By Dr Aaron Motsoaledi Minister of Health South TB in the Southern African mining sector and across the sub-region STOP TB Partnership Board Meeting By Dr Aaron Motsoaledi Minister of Health South Africa 1 Framing the Public Health Challenge Africa

More information